Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women.
Evaluation of: Lyytinen H, Pukkala E, Ylikorkala O: Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet. Gynecol. 108(6), 1354-1360 (2006) [1] . A cohort study of 84,729 Finnish women over the age of 50 years who used oral or transdermal estradiol for at least 6 months, followed for the incidence of breast cancer using a national cancer registry. The study was conducted to evaluate whether the risk of breast cancer with estrogen-only therapy varies by dose, constituents or route of administration. A total of 2171 women developed breast cancer, with no increased risk observed for less than 5 years of use, and some risk for greater than 5 years of use for both oral and transdermal routes of administration.
Division of General Internal Medicine, New York University School of Medicine, VA New York Harbor HCS, 423 E. 23rd Street - 15N, New York, NY 10010, USA. nirav.shah@med.nyu.edu.
Tanping
T
Wong
Nirav R
NR
Shah